Skip to main content

Specialty Pharmacy

  • Omicare splits business into long-term care, specialty care groups

    COVINGTON, Ky. A company that provides pharmaceutical care for the elderly is splitting its pharmacy services business into two divisions, hoping to make its services more effective and focused on customers.

     

  • Eden, Crucell ink manufacturing agreement

    RESEARCH TRIANGLE PARK, N.C. Watson Pharmaceuticals biotech subsidiary Eden Biodesign has signed a manufacturing agreement with Dutch biotech company Crucell that will give Watson access to Crucell’s cell line technology, the two companies announced Wednesday.

     

    Under the agreement, Eden will provide process development and current good manufacturing practice services using Crucell’s PER.C6 technology to licensees using the technology to develop vaccines and gene therapies.

     

     

  • Report: FDA’s Hamburg says creating biosimilars pathway likely to be complex

    NEW YORK To express it in modern parlance, follow-on biologics will be a hot mess.

     

    While speaking at the Reuters Health Summit, according to Reuters, Food and Drug Administration commissioner Margaret Hamburg didn’t put it quite that colorfully, but she had said the science will evolve, meaning a regulatory approval pathway never will be a truly done deal.

     

     

  • FDA grants fast-track designation for CDI vaccine

    SWIFTWATER, Pa. A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited approval by the Food and Drug Administration.

     

    French drug maker Sanofi-Aventis announced Tuesday that it had received fast-track designation from the FDA for its investigational Clostridium difficile vaccine. The FDA grants the designation to ease the development of new drugs and vaccines for serious or life-threatening conditions or unmet medical needs.

     

     

  • Armada Health Care expects boost in summit attendance

  • Lilly to acquire Avid

    INDIANAPOLIS and PHILADELPHIA Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease drug pipeline.

  • Sanofi-Aventis: Dengue fever vaccine in clinical development

    LYON, France A vaccine for the mosquito-borne illness dengue fever is in the final stages of development, Sanofi-Aventis said Thursday.

     

    Sanofi said the first phase-3 trial of the vaccine was under way in Australia.

     

     

  • Biogen Idec, Cardiokine terminate lixivaptan agreement

    WESTON, Mass. Swiss drug maker Biogen Idec and U.S. drug maker Cardiokine have terminated an agreement to develop a treatment for abnormally low sodium levels in the blood, the two companies said Wednesday.

     

    The agreement will give Cardiokine all rights to lixivaptan, a treatment for the condition, known as hyponatremia. The collaboration began in 2007, and the drug is in late-stage clinical studies.

     

     

X
This ad will auto-close in 10 seconds